Department of Medical Oncology, Erciyes University Medical School, Kayseri, Turkey.
Neoplasma. 2012;59(1):38-42. doi: 10.4149/neo_2012_005.
This study was aimed to establish clinical efficacy and tolerability of gemcitabine and cisplatin combination in patients with metastatic triple negative breast cancer progressing after anthracycline and taxane based chemotherapies.Thirty-three patients who were given cisplatin and gemcitabine for triple negative and metastatic breast cancer were evaluated retrospectively. A total of 141 cycles were administered with a median 4 cycles per patient. Median follow-up time was 14 months (range, 2-36 months). Objective response rate was 27.3%. Total clinical benefit of the combination was 48.4%. The estimated median progression free survival and median overall survival were 5 months and 14 months, respectively. The most common Grade 3 and 4 toxicity were neutropenia and thrombocytopenia observed in 10 (27.7%) and 9 (24.9%) patients, respectively. The combination of the gemcitabine and cisplatin after taxane/anthracycline is well tolerated and seems to be effective with acceptable toxicity profile.
本研究旨在评估吉西他滨和顺铂联合方案治疗蒽环类和紫杉类化疗后进展的转移性三阴性乳腺癌患者的临床疗效和耐受性。回顾性分析了 33 例接受吉西他滨和顺铂治疗的三阴性转移性乳腺癌患者。中位治疗 4 个周期，每个患者接受了 141 个周期。中位随访时间为 14 个月（范围 2-36 个月）。客观缓解率为 27.3%。联合治疗的总临床获益率为 48.4%。估计无进展生存期和总生存期的中位数分别为 5 个月和 14 个月。最常见的 3 级和 4 级毒性为中性粒细胞减少症和血小板减少症，分别有 10（27.7%）和 9（24.9%）例患者出现。吉西他滨和顺铂联合方案在紫杉类/蒽环类药物治疗后具有良好的耐受性，且疗效显著，毒性可耐受。
